Do Physicians Have High Hopes for LDL-Lowering Therapies in Cardiovascular Outcomes? As one of the most prevalent diseases in the major pharmaceutical markets, dyslipidemia represents a compelling…
Are Emerging Fixed-Dose Combinations Poised to Fill the Unmet Need for Drugs with Greater Efficacy? Type 2 diabetes is a major public health concern, affecting more than 30 million people in the…
Are Emerging Fixed-Dose Combinations Poised to Fill the Unmet Need for Drugs with Greater Efficacy? Type 2 diabetes is a major public health concern, affecting more than 30 million people in the…
With the High Efficacy Bar That TNF-Alpha Inhibitors Set, What Are the Remaining Areas of Opportunities for Emerging Therapies to Fill? Nine biologics are approved to treat rheumatoid arthritis (…
With the High Efficacy Bar That TNF-Alpha Inhibitors Set, What Are the Remaining Areas of Opportunities for Emerging Therapies to Fill? Nine biologics are approved to treat rheumatoid arthritis (…
Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness. More than half of advanced AMD patients suffer the wet (exudative, neovascular) form of the disease,…
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically-important Gram-positive pathogen in both the hospital and outpatient settings. Over the past decade, the MRSA hospital market has…
This quarterly report provides a detailed analysis of emerging and current therapies in nephrology based on responses from surveyed U.S. nephrologists. Emphasis is on anemia management (ESAs and IV…
The market opportunity for hepatitis C virus (HCV) is marked by a large prevalent population and high unmet medical need due to the suboptimal tolerability and efficacy of early, interferon-based…
Huntington’s disease (HD) is a fatal neurodegenerative disease characterized by uncoordinated and uncontrollable movements, cognitive deterioration, as well as behavioral and/or psychological…
The treatment armamentarium for chronic myelogenous leukemia (CML) in Brazil and Mexico includes all three currently marketed tyrosine kinase inhibitors (TKIs): Glivec (imatinib,Novartis) for newly…
Oncologists Are Eager for Therapies Extending Overall Survival Ovarian cancer (CaO) ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female…
What Do Physicians and U.S. Payers Expect from the First-to-Market Therapies Targeting Geographic Atrophy? Geographic atrophy (GA) is the advanced dry form of age-related macular degeneration (AMD…
What Do Physicians and U.S. Payers Expect from the First-to-Market Therapies Targeting Geographic Atrophy? Geographic atrophy (GA) is the advanced dry form of age-related macular degeneration (AMD…
In Europe, multiple myeloma (MM) treatment is centered on the use of three major agents—Janssen’s Velcade (bortezomib), Celgene’s Revlimid (lenalidomide), and Celgene’s Thalidomide (…